Abraxane (paclitaxel protein-bound particles; albumin-bound)
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Abraxane:
BMS Oncology Co-Pay Assistance Program
Bristol Myers Squibb Patient Assistance Foundation
Afinitor (everolimus) Tablets
Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Afinitor:
Novartis Oncology Universal Co-Pay Program
Novartis Patient Assistance Foundation
Arimidex (anastrozole) Tablets
ANI Pharmaceuticals offers 1 financial assistance program for patients who have been prescribed Arimidex:
Arimidex Patient Direct Program
Aromasin (exemestane) Tablets
Pfizer Oncology Together offers 1 financial assistance program for patients using Aromasin:
Pfizer Patient Assistance Program
Ellence (epirubicin hydrochloride) Injection
Pfizer Oncology Together offers 1 financial assistance program for patients using Ellence:
Pfizer Patient Assistance Program
Enhertu (fam-trastuzumab) Injection
Daiichi Sankyo and AstraZeneca offer 2 patient assistance programs for patients who have been prescribed Enhertu:
Enhertu Patient Savings Program
Enhertu Patient Assistance Program
Fareston (toremifene citrate) Tablets
Kyowa Kirin, through Patient Rx Solutions, offers 2 financial assistance programs for patients using Fareston:
Fareston Copay Assistance Card Program
Fareston Patient Assistance Program
Faslodex (fulvestrant)
AstraZeneca Access 360 offers 2 financial assistance programs for patients using Faslodex:
FASLODEX Co-pay Savings Program
AZ&Me Prescription Savings Program
Halaven (eribulin mesylate)
Eisai offers 2 financial assistance programs for patients using Halaven:
Halaven $0 Co-Pay Program
Halaven Patient Assistance Program
Herceptin (trastuzumab)
Genentech Oncology offers 2 financial assistance programs for patients using Herceptin:
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection
Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Herceptin Hylecta:
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation
Ibrance (palbociclib) Capsules/Tablets
Pfizer Oncology Together offers 2 financial assistance programs for patients using Ibrance:
Pfizer Oncology Together Co-Pay Savings Program
Pfizer Patient Assistance Program
Ixempra (ixabepilone)
R-Pharm US offers 1 financial assistance program for patients using Ixempra:
R-Pharm US Access + Support Program
Kadcyla (ado-trastuzumab emtansine)
Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Kadcyla:
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation
Kanjinti (trastuzumab-anns) Injection
Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Kanjinti:
Amgen FIRST STEP Co-Pay Program
Amgen Safety Net Foundation
Keytruda (pembrolizumab)
Merck offers 2 financial assistance programs for patients who have been prescribed Keytruda:
Merck Co-pay Assistance Program
Merck Patient Assistance Program
Kisqali (ribociclib) Tablets
Novartis Patient Assistance NOW Oncology offers 4 financial assistance programs for patients using Kisqali:
Kisqali Free Treatment Voucher
Kisqali 5-Treatment Cycle Access Program
Novartis Oncology Universal Co-pay Program
Novartis Patient Assistance Foundation
Lynparza (olaparib) Capsules/Tablets
AstraZeneca offers 2 financial assistance programs for patients using Lynparza:
Lynparza Co-pay Savings Program
AZ&Me Prescription Savings Program
Margenza (margetuximab-cmkb) Injection
MacroGenics, through Margenza Access Support, offers 2 financial assistance programs for patients using Margenza:
Margenza Copay Assistance Program
Margenza Patient Assistance Program
Nerlynx (neratinib) Tablets
Puma Biotechnology offers 3 financial assistance programs for patients using Nerlynx:
Puma Patient Lynx Co-Pay Savings Program
Nerlynx Patient Assistance Program
Nerlynx Quick Start Program
Ogivri (trastuzumab-dkst) Injection
Mylan, through Viatris Advocate, offers 2 financial assistance programs for patients who have been prescribed Ogivri:
Mylan Advocate Co-Pay Assistance Program
Mylan Advocate Patient Assistance
Ontruzant (trastuzumab-dttb) for Injection
Organon Access Program offers 2 financial assistance programs for patients using Ontruzant:
Organon Co-Pay Assistance Program
Organon Patient Assistance Program
Perjeta (pertuzumab)
Genentech Oncology offers 2 financial assistance programs for patients using Perjeta:
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation
Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection
Genentech Oncology offers 2 financial support programs for patients who have been prescribed Phesgo:
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation
Piqray (alpelisib) Tablets
Novartis Patient Assistance NOW Oncology offers 3 financial assistance programs for patients who have been prescribed Piqray:
Novartis Oncology Universal Co-pay Program
Free Trial Program and Access Program
Novartis Patient Assistance Foundation
Talzenna (talazoparib) Capsules
Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Talzenna:
Pfizer Oncology Together Co-Pay Savings Card
Pfizer Patient Assistance Program
Tecentriq (atezolizumab)
Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Tecentriq:
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation
Trazimera (trastuzumab-qyyp)
Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Trazimera:
Pfizer Oncology Together Co-Pay Savings Program
Pfizer Patient Assistance Program
Trodelvy (sacituzumab govitecan-hziy) Injection
Gilead, through Trodelvy Access Support, offers 2 financial assistance programs for patients who have been prescribed Trodelvy:
Trodelvy Savings Program
Gilead Patient Assistance Program
Tukysa (tucatinib) Tablets
Seagen Secure offers 2 financial assistance programs for patients who have been prescribed Tukysa:
Commercial Out-of-Pocket Assistance Program
Patient Assistance Program
Tykerb (lapatinib) Tablets
Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tykerb:
Novartis Oncology Universal Co-pay Program
Novartis Patient Assistance Foundation
Verzenio (abemaciclib) Tablets
Lilly Oncology offers 2 financial assistance programs for patients who have been prescribed Verzenio:
Verzenio Continuous Care Program
Verzenio Savings Card
Xeloda (capecitabine) Tablets
Genentech Oncology offers 1 financial support assistance program for patients who have been prescribed Xeloda:
Genentech Patient Foundation
Zoladex (goserelin) Implant
TerSera Therapeutics offers 2 financial assistance programs for patients who have been prescribed Zoladex:
Zoladex Copay Card
Zoladex Patient Assistance Program
Table. Drugs Prescribed for Breast Cancer
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Abraxane (paclitaxel protein-bound particles; albumin-bound)
- Bristol Myers Squibb
- Metastatic breast cancer after failure of chemotherapy
- BMS Oncology Co-Pay Assistance Program
800-861-0048
Bristol Myers Squibb Patient Assistance Foundation
800-736-0003
- Afinitor (everolimus) Tablets
- Novartis
- Postmenopausal women with advanced HR-positive, HER2-negative breast cancer, in combination with Aromasin
- Novartis Oncology Universal Co-Pay Program
877-577-7756
Novartis Patient Assistance Foundation
800-277-2254
- Arimidex (anastrozole) Tablets
- ANI Pharmaceuticals
- Postmenopausal, HR-positive
early breast cancer
First-line treatment of postmenopausal HR-positive or HR-unknown, locally advanced or metastatic breast cancer
Second-line treatment of postmenopausal advanced breast cancer after Nolvadex or Soltamox therapy - Arimidex Patient Direct Program
855-250-2483
- Aromasin (exemestane) Tablets
- Pfizer
- Postmenopausal ER-positive
early breast cancer
Postmenopausal advanced breast cancer, after Nolvadex or Soltamox therapy - Pfizer Patient
Assistance Program
877-744-5675
- Ellence (epirubicin hydrochloride) Injection
- Pfizer
- Axillary node tumor, after resection of primary breast cancer
- Pfizer Patient Assistance Program
877-744-5675
- Enhertu (fam-trastuzumab) Injection
- Daiichi Sankyo and AstraZeneca
- Treatment of adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH‑) breast cancer who have received chemotherapy for metastatic disease or disease recurrence during or within 6 months of completing adjuvant chemotherapy
- Enhertu Patient Savings Program
833-364-3788
Enhertu Patient Assistance Program
833-364-3788
- Fareston (toremifene citrate) Tablets
- Kyowa Kirin
- Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumors
- Fareston Copay
Assistance Card Program
844-214-3442
Fareston Patient Assistance Program
844-214-3442
- Faslodex (fulvestrant)
- AstraZeneca
- First-line treatment of HRpositive,
HER2-negative
advanced breast cancer in
postmenopausal women
who have not received
endocrine therapy
HR-positive metastatic breast cancer in postmenopausal women, after anti-estrogen therapy
HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Ibrance or with Verzenio - FASLODEX Co-pay Savings Program
844-275-2360
AZ&Me Prescription Savings Program
844-275-2360
- Halaven (eribulin mesylate) Injection
- Eisai
- Metastatic breast cancer, after chemotherapy and an anthracycline and a taxane therapy
- Halaven $0 Co-Pay Program
866-613-4724
Halaven Patient Assistance Program
866-613-4724
- Herceptin (trastuzumab)
- Genentech
- HER2-overexpressing breast cancer
- Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection
- Genentech
- Adjuvant treatment of
HER2-positive breast cancer,
in combination with chemotherapy,
or alone after multiple
anthracycline-based therapies
Treatment of HER2-positive metastatic breast cancer, after 1 or more chemotherapies for metastatic disease - Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Ibrance (palbociclib) Capsules/Tablets
- Pfizer
- Treatment of HR-positive,
HER2-negative advanced or metastatic
breast cancer, in combination
with an aromatase inhibitor
as initial endocrine-based
therapy, in postmenopausal
women, or in men
Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, in adults whose disease progressed after endocrine therapy - Pfizer Oncology Together Co-Pay Savings Program
877-744-5675
Pfizer Patient Assistance Program
877-744-5675
- Ixempra (ixabepilone)
- R-Pharm US
- Metastatic or locally advanced
breast cancer, in combination
with Xeloda
Metastatic or locally advanced breast cancer, after failure of an anthracycline, a taxane, and Xeloda - R-Pharm US Access + Support Program
855-991-7277
- Kadcyla (ado-trastuzumab emtansine)
- Genentech
- HER2-positive metastatic
breast cancer, after Herceptin
and/or a taxane
Adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease, after neoadjuvant taxane and trastuzumab-based treatment - Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Kanjinti (trastuzumab-anns) Injection
- Amgen
- Treatment of HER2-overexpressing breast cancer
- Amgen FIRST STEP Co-Pay Program
866-264-2778
Amgen Safety Net Foundation
866-264-2778
- Keytruda (pembrolizumab)
- Merck
- Treatment, in combination with
chemotherapy, of patients with
locally recurrent unresectable
or metastatic triple-negative
breast cancer whose tumors
express PD-L1, as determined
by an FDA-approved
test
Treatment of patients with highrisk, early-stage, triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, and then continued alone as adjuvant treatment after surgery - Merck Co-pay Assistance Program
855-257-3932
Merck Patient Assistance Program
855-257-3932
- Kisqali (ribociclib) Tablets
- Novartis
- Treatment of postmenopausal
women with HR-positive,
HER2-negative
advanced or
metastatic breast cancer, in
combination with an aromatase
inhibitor
Treatment, in combination with Faslodex, of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrinebased therapy or after disease progression with endocrine therapy - Kisqali Free Treatment Voucher
877-744-5675
Kisqali 5-Treatment Cycle Access Program
800-282-7630
Novartis Oncology Universal Co-pay Program
877-577-7756
Novartis Patient Assistance Foundation
800-277-2254
- Lynparza (olaparib) Capsules/Tablets
- AstraZeneca
- Treatment of deleterious or
suspected deleterious germline
BRCA mutation-positive, HER2-
negative metastatic breast
cancer, after chemotherapy
Adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib - Lynparza Co-pay Savings Program
844-275-2360
AZ&Me Prescription Savings Program
800-292-6363
- Margenza (margetuximab-cmkb) Injection
- MacroGenics
- Treatment, in combination with chemotherapy, of adults with metastatic HER2-positive breast cancer who have received 2 or more previous anti-HER2 regimens, at least 1 of which was for metastatic disease
- Margenza Copay
Assistance Program
844-633-6469
Margenza Patient Assistance Program
844-633-6469
- Nerlynx (neratinib) Tablets
- Puma Biotechnology
- Treatment, in combination with Xeloda, of adults with advanced or metastatic HER2-positive breast cancer who have received 2 or more previous anti-HER2 regimens for metastatic disease
- Puma Patient Lynx Co-pay Savings Program
855-816-5421
Nerlynx Patient Assistance Program
855-816-5421
Nerlynx Quick Start Program
855-816-5421
- Ogivri (trastuzumab-dkst) Injection
- Mylan
- Treatment of HER2-overexpressing breast cancer
- Mylan Advocate Co-Pay Assistance Program
833-695-2623
Mylan Advocate Patient Assistance
833-695-2623
- Ontruzant (trastuzumab-dttb) Injection
- Organon
- First-line treatment, in
combination with paclitaxel,
of HER2-overexpressing
metastatic breast cancer
Treatment of HER2- overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease - Organon Co-pay Assistance Program
844-326-2986
Organon Patient Assistance Program
844-326-2986
- Perjeta (pertuzumab)
- Genentech
- HER2-positive metastatic
breast cancer, in combination
with Herceptin and Taxotere
Neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, in combination with Herceptin and Taxotere - Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection
- Genentech
- Neoadjuvant treatment, in
combination with chemotherapy,
of patients with HER2-positive,
locally advanced, inflammatory,
or early-stage breast cancer
Adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence
Treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease - Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Piqray (alpelisib) Tablets
- Novartis
- Treatment of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer and PIK3CA mutation, whose disease progressed during or after endocrine therapy, in combination with fulvestrant
- Novartis Oncology Universal Co-pay Program
877-577-7756
Free Trial Program and Access Program
800-282-7630
Novartis Patient Assistance Foundation
800-277-2254
- Talzenna (talazoparib) Capsules
- Pfizer
- HER2-negative locally advanced or metastatic breast cancer with germline BRCA mutations
- Pfizer Oncology Together Co-Pay Savings Card
877-744-5675
Pfizer Patient Assistance Program
877-744-5675
- Tecentriq (atezolizumab)
- Genentech
- Treatment, in combination with Abraxane, of unresectable, locally advanced or metastatic triple-negative breast cancer expressing PD-L1, as determined by an FDA-approved test
- Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Trazimera (trastuzumab-qyyp)
- Pfizer
- Adjuvant treatment, in
combination with various
chemotherapy regimens,
of patients with HER2-overexpressing node-positive or
node-negative breast cancer
Treatment of HER2-overexpressing breast cancer as a single agent, after anthracycline-based therapy
First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer
Treatment of HER2-overexpressing metastatic breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease - Pfizer Oncology Together Co-Pay Savings Program
877-744-5675
Pfizer Patient Assistance Program
877-744-5675
- Trodelvy (sacituzumab govitecan-hziy) Injection
- Gilead
- Treatment of adults with metastatic triple-negative breast cancer who have received at least 2 previous therapies for metastatic disease
- Trodelvy Savings Program
844-876-3358
Gilead Patient Assistance Program
844-876-3358
- Tukysa (tucatinib) Tablets
- Seagen
- Treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received 1 or more previous anti-HER2 regimens for metastatic disease
- Commercial Out-of-Pocket Assistance Program
855-473-2873
Patient Assistance Program
855-473-2873
- Tykerb (lapatinib) Tablets
- Novartis
- Advanced or metastatic breast
cancer overexpressing HER2, in
combination with Xeloda, after
an anthracycline, a taxane, and
Herceptin
Postmenopausal, HR-positive metastatic breast cancer overexpressing HER2, in combination with Femara - Novartis Oncology Universal Co-pay Program
877-577-7756
Novartis Patient Assistance Foundation
800-277-2254
- Verzenio (abemaciclib) Tablets
- Eli Lilly
- Adjuvant treatment, in
combination with endocrine
therapy, tase inhibitor) of adults
with HR-positive, HER2-negative,
node-positive, early breast cancer
at high risk of recurrence and
a Ki-67 score at least 20%, as
determined by an FDA-approved
test
As initial endocrine-based treatment, in combination with an aromatase inhibitor, of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer
Treatment, in combination with fulvestrant, of adults with HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy
Treatment (alone) of adults with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy and before chemotherapy in the metastatic setting - Verzenio Continuous Care Program
844-837-9364
Verzenio Savings Card
844-837-9364
- Xeloda (capecitabine) Tablets
- Genentech
- Metastatic breast cancer, in combination with Taxotere, after failure of anthracyclinecontaining therapy
- Genentech Patient Foundation
888-941-3331
- Zoladex (goserelin) Implant
- TerSera Therapeutics
- Palliative treatment, in combination with flutamide, of premenopausal or perimenopausal women with advanced breast cancer
- Zoladex Copay Card
844-864-3014
Zoladex Patient Assistance Program
855-686-8725